IMDX vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IMDX exhibits severe financial distress, anchored by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from negative equity (Price/Book: -2.89) and a catastrophic operating margin of -873.57%, suggesting an unsustainable business model. Revenue is contracting rapidly (-23.4% YoY), and the earnings track record is abysmal with 0 beats in the last four quarters. Despite optimistic analyst price targets, the deterministic data points toward a high risk of insolvency or significant further dilution.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
IMDX vs JNJ: Head-to-Head Comparison
This page compares Insight Molecular Diagnostics Inc. (IMDX) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.